Tempus has set a revenue target between $1.595 billion and $1.605 billion [1] for 2026.
This financial outlook signals the company's attempt to scale its precision medicine footprint through a combination of new product approvals and strategic market expansions.
The updated projections follow a Q2 2026 earnings call recap where the company reported 22% revenue growth [1]. Tempus said it has raised its 2026 guide [1] to reflect this upward trajectory.
A significant portion of the long-term growth strategy relies on the xT CDx and xF products. Tempus expects these tools to drive a $400 million uplift [1] by 2028. This growth is tied to the FDA approval of these specific diagnostics, a move that allows the company to integrate more deeply into clinical workflows.
Beyond product approvals, the company is leveraging a deal with Personalis to bolster its capabilities. The combination of these partnerships, and the rollout of xT CDx and xF, is intended to accelerate the company's ability to provide data-driven insights for cancer treatment.
Tempus continues to focus on the intersection of artificial intelligence and genomic sequencing to maintain its growth rate. By increasing the volume of clinical data processed through its platforms, the company aims to secure its position in the expanding precision oncology market.
“"22% revenue growth,"”
The aggressive revenue targets and the specific $400 million uplift projection indicate that Tempus is shifting from a foundational data-gathering phase to a commercialization phase. By securing FDA approval for xT CDx and xF, the company is moving beyond research into regulated diagnostic markets, which typically allows for more stable reimbursement and wider clinical adoption.
